Pharmaceutical CMO and CDMO Market Intelligence in Outsourced Pharma Manufacturing

Revenue, 2025

USD 156.93 Billion

Forecast, 2035

USD 340.37 Billion

CAGR, 2026-2035

8.05%

Report Coverage

Global

Pharmaceutical CMO and CDMO Market Trends for 2026

The global pharmaceutical CMO and CDMO market size was estimated at USD 156.93 billion in 2025 and is predicted to increase from USD 169.56 billion in 2026 to approximately USD 340.37 billion by 2035, expanding at a CAGR of 8.05% from 2026 to 2035.

The growing advancements in advanced therapies, vaccines, and biologics are increasing the demand for pharmaceutical CMO and CDMO services. Increasing outsourcing trends, growing innovations, and technological advancements are also promoting the market growth.

Key Takeaways

• The pharmaceutical CMO and CDMO market will likely exceed USD 169.56 billion by 2026.
• Valuation is projected to hit USD 340.37 billion by 2035.
• Estimated to grow at a CAGR of 8.05% starting from 2026 to 2035.
• North America held a majority revenue share of the global pharmaceutical CMO and CDMO market in 2025.
• Asia Pacific is expected to be the fastest-growing region between 2026 and 2035.
• By service type, the API manufacturing segment dominated the market in 2025.
• By service type, the finished dosage formulation segment is expected to witness the fastest growth during the forecast period.
• By product type, the small molecule segment held the largest revenue share of the market in 2025.
• By product type, the biologics segment is expected to be the fastest-growing during the forecast period.
• By end-user, the pharmaceutical companies segment contributed the biggest revenue share of the market in 2025.
• By end-user, the biotechnology companies segment is expected to witness the fastest growth during the forecast period.

What is the Pharmaceutical CMO and CDMO?

The pharmaceutical CMO and CDMO market is driven by the increasing complexity of the modern drug pipeline. The pharmaceutical CMO and CDMO refer to the specialized service providers offering outsourced drug manufacturing and/or development services from R&D to commercialization. They offer affordable services, fastest drug development, and regulatory expertise, which attract the industry.

What are the Applications of AI in the Market?

AI offers a wide range of applications, such as optimization of drug formulations, process optimization, and faster product development timelines in the pharmaceutical CMO and CDMO market. Moreover, its real-time data analysis, predictive maintenance, and batch optimization help in maintaining product quality and reducing the chance of errors. Additionally, its quality control, regulatory compliance, automated documentation, inventory management, and evidence-based insights are also increasing its demand.

Trends & Future Outlook of the Market

Escalation of Complex Dosage Forms

The growing diseases and R&D activities are promoting the development of orphan drugs, personalized treatment, and high-value niche therapies, which are increasing the demand for specialized manufacturing services, leading to a rise in the demand for pharmaceutical CMOs and CDMOs.

Increased Biologics and Biosimilar Manufacturing

The growing health awareness is increasing the adoption of biologic, biosimilar, and gene and cell therapies, which is increasing the collaborations with the pharmaceutical CMO and CDMOs to leverage their services and regulatory expertise.

Increased Advanced Technology Adoption

To enhance operational efficiency, regulatory compliance, and maintain product quality, the pharmaceutical CMOs and CDMOs are utilizing advanced technologies, promoting automation, continuous manufacturing, predictive analytics, etc.

Executive Summary Table

Segmental Insights

By Service Type Insights

Why Did the API Manufacturing Segment Dominate in the Market in 2025?

The API manufacturing segment led the pharmaceutical CMO and CDMO market in 2025, as they are essential for the production of drugs. The growth in the demand for generic and branded drugs also increased the use of these services. Moreover, growth in the investments and outsourcing trends also increased their use.

Finished Dosage Formulation

The finished dosage formulation segment is expected to show the highest growth during the upcoming years, due to the growing development of vaccines and other injectable products. Additionally, expanding development of modified release and combination products is also increasing the demand for finished dosage formulation services.

By Product Type Insights

Which Product Type Segment Held the Dominating Share of the Market in 2025?

The small molecule segment held the dominating share of the pharmaceutical CMO and CDMO market in 2025, due to growth in their approval rates. Increased rate of generic small molecule production, along with increased outsourcing, led to growth in the pharmaceutical CMO and CDMO collaborations.

Infographics 

Biologics

The biologics segment is expected to expand rapidly in the market during the predicted time, due to growing demand for targeted therapies. Similarly, increasing development of monoclonal antibodies and specialized therapies is also increasing the use of pharmaceutical CMO and CDMO services, where the growing clinical trials are also increasing their demand.

By End-User Insights

What Made Pharmaceutical Companies the Dominant Segment in the Market in 2025?

The pharmaceutical companies segment registered its dominance over the global pharmaceutical CMO and CDMO market in 2025, due to growth in the manufacturing process. The increased R&D activities and investments also increased the partnership with the pharmaceutical CMO and CDMOs to leverage their advanced technologies and expertise.

Biotechnology Companies

The biotechnology companies segment is expected to show the highest growth during the upcoming years, due to growing advancements in biologics, orphan drugs, and personalized therapies development. The expanding startup ecosystems and funding are also increasing the collaboration with the pharmaceutical CMOs and CDMOs.

Regional Insights

How Do Advanced Companies Drive North America?

North America dominated the pharmaceutical CMO and CDMO market in 2025, due to the presence of well-developed pharmaceutical and biotechnology companies, which actively participated in the clinical trials and R&D activities. This increased the demand for pharmaceutical CMO and CDMO to leverage their services, advanced facilities, and technologies, which contributed to the market growth.

U.S. Market Trends

The U.S. is a home for top pharmaceutical and biotechnology companies, which are increasing the advancements in R&D and clinical trials, leading to a growth in the reliance on the pharmaceutical CMO and CDMOs. Their advanced manufacturing facilities, stringent regulatory compliance, and advanced technologies are also increasing their collaborations.

What Factor Boosts Asia Pacific?

Asia Pacific is expected to host the fastest-growing pharmaceutical CMO and CDMO market during the forecast period, due to expanding manufacturing capabilities and increasing generic drug production. Additionally, expanding industries, growing demand for biologics, vaccines, and increasing clinical trials are also driving the demand for pharmaceutical CMO and CDMO, enhancing the market growth.

India Market Trends

India is experiencing a rapid growth in the biotech sector, driving the development of biological, advanced therapies, biosimilars, and specialty drugs, which is leading to a growth in strategic partnerships with the pharmaceutical CMO and CDMOs. Growing government initiatives, generic products development, and affordable manufacturing services are also increasing their acceptance rates.

Is Europe Driven by a Robust R&D Ecosystem?

Europe is expected to grow significantly in the pharmaceutical CMO and CDMO market during the forecast period, due to the presence of robust R&D ecosystems, advanced pharmaceutical and biotech hubs, and stringent regulations, which encourage the use of pharmaceutical CMO and CDMOs. The growing demand for cell and gene therapies is also driving their demand, promoting market growth.

UK Market Trends

The UK consists of a well-established pharmaceutical and biotechnology hub, which is increasing the number of innovations. The universities and research institutes are also increasing their R&D activities focused on the development of small molecules and biologics, which is leading to new collaborations with the pharmaceutical CMOs and CDMOs.

Market Value Chain Analysis

R&D

• The R&D of the pharmaceutical CMO and CDMO focuses on the utilization of specialized platforms, AI-driven process optimization, and continuous manufacturing for complex modalities.
• Key players: Lonza Group, Thermo Fisher Scientific, Catalent, Inc.

Clinical Trials and Regulatory Approvals

• The data integrity, stability, consistency, process validation, and good manufacturing practice (GMP) compliance are evaluated in the clinical trials and regulatory approvals of the pharmaceutical CMO and CDMO.
• Key players: Lonza Group, Thermo Fisher Scientific, Catalent, Inc.

Packaging and Serialization

• The packaging and serialization of the pharmaceutical CMO and CDMO involve the integration of track-and-trace technologies, automated aggregation systems, and tamper-evident designs.
• Key players: Thermo Fisher Scientific, Catalent, Inc., and Recipharm AB.

Patient Support and Services

• The direct-to-patient (DtP) clinical trial logistics, digital adherence tools, and home nursing coordination are provided in the patient support and services of the pharmaceutical CMO and CDMO.
• Key players: Thermo Fisher Scientific, Catalent, Inc., and Almac Group.

Who are the Market Top Vendors and What are Their Offerings?

SWOT Analysis

Strengths

• The pharmaceutical CMO and CDMO offer affordable manufacturing services along with end-to-end services, which increases their adoption rates.
• They also offer scalable production from clinical to commercial, which is driving their demand.
• Their formulation, process, and regulatory expertise also increase their use.
• The presence of advanced technologies is also increasing their use in the development of new products.

Weaknesses

• The high capital investments for facilities, equipment, and R&D activities act as a major weakness in the pharmaceutical CMO and CDMO market, limiting their use.
• Dependence on the client's contract also limits their growth.

Opportunities

• The growing R&D activities are increasing the outsourcing trends, driving the demand for pharmaceutical CMO and CDMO services.
• The growing advancements in the generics drug development are also increasing the demand for their end-to-end services.
• The growing biologics and biosimilar adoption rates are also increasing their use to leverage various services.
• Expanding industries are also increasing the collaboration with the pharmaceutical CMO and CDMO.

Threats

• Long development timelines and high operational complexity reduce collaboration with the pharmaceutical CMO and CDMO.
• Regulatory burden and shortage of experts also limit their use.

What are the Recent Developments in the Market?

• In November 2025, a significant CDMO partnership between HRV Pharma and MetroChem API was announced, which will support the advanced API development in India, where it will provide scale-up and end-to-end GMP manufacturing and exclusive and semi-exclusive development for multiple strategic molecules.
• In March 2025, a 'hybrid' CDMO model was launched by Indian CDMO, Shilpa Medicare, at DCAT 2025, which will support ready off-the-shelf novel formulations for exclusive b2b licensing.

Segments Covered in the Report

By Service Type

• API Manufacturing
• Finished Dosage Formulation
• Packaging
• Others

By Product Type

• Small Molecule
• Biologics

By End-User

• Pharmaceutical Companies
• Biotechnology Companies
• Others

By Region

• North America
  • U.S.
  • Canada 
  • Mexico 
  • Rest of North America
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Europe 
  • Western Europe 
    • Germany 
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal 
    • Belgium
    • Ireland
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus 
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan
  • India 
  • Japan 
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar 
    • Kuwait 
    • Oman 
    • Bahrain 
  • South Africa
  • Egypt 
  • Rest of MEA